Citigroup
HOWL icon

Citigroup’s Werewolf Therapeutics HOWL Stock Holding History

Citigroup’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.82K Buy
3,384
+3,383
+338,300% +$2.32K ﹤0.01% 5374
2025
Q4 		$1 Sell
1
-8,660
-100% -$10.5K ﹤0.01% 5972
2025
Q3 		$17.1K Buy
8,661
+8,340
+2,598% +$11.4K ﹤0.01% 4870
2025
Q2 		$350 Sell
321
-21,586
-99% -$22.2K ﹤0.01% 5459
2025
Q1 		$21.3K Sell
21,907
-1,822
-8% -$2.39K ﹤0.01% 5078
2024
Q4 		$35.1K Buy
23,729
+718
+3% +$1.46K ﹤0.01% 5175
2024
Q3 		$48.8K Buy
23,011
+16,220
+239% +$36.9K ﹤0.01% 5031
2024
Q2 		$16.6K Sell
6,791
-64,765
-91% -$311K ﹤0.01% 5045
2024
Q1 		$464K Buy
+71,556
New +$417K ﹤0.01% 3628
2023
Q1 		– Sell
-74
Closed -$152 – 5651
2022
Q4 		$152 Sell
74
-353
-83% -$923 ﹤0.01% 5615
2022
Q3 		$2K Sell
427
-309
-42% -$1.68K ﹤0.01% 5499
2022
Q2 		$3K Sell
736
-1,946
-73% -$8.88K ﹤0.01% 5775
2022
Q1 		$12K Sell
2,682
-5,238
-66% -$36.7K ﹤0.01% 5428
2021
Q4 		$94K Buy
7,920
+7,053
+813% +$106K ﹤0.01% 4762
2021
Q3 		$15K Sell
867
-1,149
-57% -$19.6K ﹤0.01% 5352
2021
Q2 		$35K Buy
+2,016
New +$27.6K ﹤0.01% 4983

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup's HOWL Position: Q1 2026 in Review

Citigroup increased its Werewolf Therapeutics (HOWL) stake by 338,300% in Q1 2026, buying an estimated $2.32K and bringing the position to 3,384 shares worth $2.82K. The position accounts for ﹤0.01% of the portfolio, ranked #5374.

Citigroup first reported a position in HOWL in Q2 2021 and has held it in 16 quarters since. The position peaked at $464K in Q1 2024. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.

  • Citigroup held 3,384 shares of Werewolf Therapeutics worth $2.82K as of Q1 2026.
  • Citigroup bought 3,383 Werewolf Therapeutics shares in Q1 2026, an estimated $2.32K.
  • Werewolf Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5374 holding.
  • Citigroup first reported a position in Werewolf Therapeutics in Q2 2021 and has held it in 16 quarters since.
  • Citigroup's Werewolf Therapeutics position peaked at $464K in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.